Zevra Therapeutics, Inc.
ZVRANASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $601.71M
- P/E (TTM)
- 10.33
- Forward P/E
- 5.96
- Dividend yield
- -
- 52-week range
- $8.01$15.04
- Volume (live)
- -
- Avg. volume (3M)
- 874.14K
Zevra Therapeutics (ZVRA) Stock Price & Financial Analysis
Zevra Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $9.76 - $10.25 |
|---|---|
| 52-Week High | $15.04 |
| 52-Week Low | $8.01 |
| Open | $10.25 |
| Volume (last close) | 978.00K |
| Average Volume (3M) | 874.14K |
| Revenue (TTM) | 136.07M |
|---|---|
| Net Income (TTM) | 58.26M |
| Free Cash Flow (TTM) | 32.62M |
| EPS (TTM) | $0.99 |
| Profit Margin | 42.82% |
| Operating Margin | 28.71% |
| Return on Equity (ROE) | 26.77% |
| Debt to Equity | 0.01 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 601.71M |
|---|---|
| Shares Outstanding | 61.34M |
| P/E Ratio (TTM) | 10.33 |
| Forward P/E | 5.96 |
| Price to Sales (P/S) | 4.42 |
| Price to Book (P/B) | 2.76 |
| EV/EBITDA | 6.36 |
| 50-Day MA | $11.40 |
|---|---|
| 200-Day MA | $10.68 |
| 1-Year Change | −3.28% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Zevra Therapeutics at a Glance
As of the Oct 23, 2026 close, Zevra Therapeutics (ZVRA) has a market capitalization of $601.71M. The stock trades at 10.3× trailing earnings, 6.0× forward earnings and 4.4× sales. Over the trailing twelve months it earned $58.26M on revenue of $136.07M (a 42.8% profit margin) and generated $32.62M of free cash flow. Revenue grew 119.4% year over year.
As of its latest reported balance sheet, it holds $145.32M in cash and securities against $1.50M of debt, a net cash position of $143.82M.
Zevra Therapeutics does not currently pay a dividend.
The share price is down 3.3% over the past year. At $9.81 (the Oct 23, 2026 close) it sits within its 52-week range of $8.01 to $15.04, below its 200-day moving average of $10.68.
Based on 9 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $25.25, 157.4% above the Oct 23, 2026 close.
Frequently Asked Questions About Zevra Therapeutics
What is the current stock price for ZVRA?
As of the Oct 23, 2026 close, ZVRA stock trades at $9.81. The 52-week range is $8.01–$15.04, with a day range of $9.76–$10.25.
What is the P/E ratio for ZVRA?
As of the Oct 23, 2026 close, Zevra Therapeutics's trailing twelve-month (TTM) P/E ratio is 10.3, meaning investors pay $10.3 for every $1 of annual earnings. The forward P/E is 6.0, reflecting analyst expectations for future earnings. Zevra Therapeutics operates in the Healthcare sector.
Does ZVRA pay dividends?
Zevra Therapeutics does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for ZVRA?
Based on ratings from 9 professional analysts over the last 90 days, the consensus for ZVRA is Buy. The average 12-month price target is $25.25, a 157.4% upside from the Oct 23, 2026 close of $9.81.
What is the market cap of ZVRA?
As of the Oct 23, 2026 close, Zevra Therapeutics's market capitalization is $601.7M, classifying it as a small-cap company. Zevra Therapeutics operates in the Healthcare sector within the Biotechnology industry.